Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

Gilead Sciences (GILD) Q1 Earnings Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of 8.64% and -0.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

What's in the Cards for Sunesis (SNSS) This Earnings Season?

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?

Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?

For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $65.15 in the latest trading session, marking a +1.57% move from the prior day.

Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?

Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.